BioSpace News Archive

- Anticipates Early Data Readout for Phase 2b Study of PTI-125 in Alzheimer’s Disease - - Approximately $2.9 Million in NIH Research Grants Awarded in 2020 - - Open-Label Study of PTI-125 Initiated in Alzheimer’s Disease -

- New corporate name, Cardiff Oncology, reflects the Company’s mission and commitment to turning the tide on cancer by developing new treatment options for cancer patients - Effective May 8th, Dr. Thomas Adams will transition his role from Chairman and CEO to Executive Chairman and Dr. Mark Erlander will assume the role of CEO - Changes mark an important milestone in the Company’s evolution and advancing development of onvansertib in cancer indications with the greatest medic

LAIX Inc. (“LAIX” or the “Company”) (NYSE: LAIX), an artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning, today announced the appointment of Mr. Bing Sun, as the Company’s new chief financial officer, effective May 6, 2020.

MathWorks today introduced Release 2020a with expanded AI capabilities for deep learning. Engineers can now train neural networks in the updated Deep Network Designer app, manage multiple deep learning experiments in a new Experiment Manager app, and choose from more network options to generate deep learning code.

Company to develop subcutaneously administered dendrimer-based anti-VEGF therapy with selective targeting in wet AMD Potential therapeutic may offer significant opportunities for degenerative retinal diseases such as wet AMD and diabetic retinopathy, and may reduce significant side effects associated with systemic treatment of ocular disease REDWOOD CITY, Calif.--( BUSINESS WIRE )-- Ashvattha Therapeutics , a biotech company focused on nove

DongWha Pharm (KRX:000020), a leading Korean pharmaceutical company, announced on April 21 st , 2020 that it plans to conduct clinical trials using a new drug candidate DW2008 to treat COVID-19. DW2008 is an extract of the water willow plant ( Justicia procumbens ). In vitro antiviral experiments performed at the Institut Pasteur Korea against COVID-19 demonstrate

ResMed announced that Rob Douglas, president and chief operating officer, will participate in a virtual fireside chat at the Bank of America Securities Healthcare Conference 2020 on Tuesday, May 12, 2020, beginning at approximately 4:20 p.m. via webcast.

Dr. Arnold S. Lippa, Ph.D. to Continue as Executive Chairman of the Board of Directors and Chief Scientific Officer

The COVID-19 pandemic is an unprecedented global health crisis, impacting all aspects of life and society.

Pear Therapeutics, Inc. today announced the launch of the PEAR Assistance Program to ensure eligible patients living with Substance Use Disorder or Opioid Use Disorder have access to FDA-authorized prescription digital therapeutics (PDTs) for addiction treatment